# Eaglenos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eaglenos

- Industry: Medical Devices & Equipment
- Headquarters: Nanjing, China
- Website: www.eaglenos.com
- Total disclosed funding: $21M
- Latest round: Series A (May 29, 2023)
- Investors on record: 4

## About

Established in 2018 and based in Nanjing, China, Eaglenos is a medical device company that focuses on developing and manufacturing precision testing and diagnostic products. The company's manufacturing team has 20 years of experience in medical device production management, more than 10 production lines, and several factory construction experiences. It received registration certificates for 11 products in 2021 and obtained ISO13485 system certification. The founder of this company, Dr. Yu Qin, graduated from Auburn University and has more than 20 years of research experience in the field of electrochemical sensors, teaching at the Department of Chemistry of the Renmin University of China and the School of Chemistry and Chemical Engineering of Nanjing University. As of 2023, it has 220 people. In May 2023, it raised CNY 150 million in series A funding led by new investor 3E Bioventures Capital, with participation from other new investors Grand Yangtze Capital, Huatai Zijin Investment, InnoMed Capital, and other unspecified investors.

The company's main business is the development, production, and sales of precision POCT and health management products. Its self-developed products include a blood glucose and uric acid tester, blood glucose and lactate tester, blood glucose and blood ketone tester, blood gas and biochemistry analyzer, electrolyte analyzer, continuous temperature monitoring patch, finger clip oximeter, and full solid-state high-resolution electrochemical microscope. Its products are used in the field of diabetes mellitus, hyperuricemia, and cardiovascular and cerebrovascular diseases.

## Funding rounds

- Series A, May 29, 2023, $21M — Grand Yangtze Capital, 3E Bioventures Capital, Huatai Zijin Investment, InnoMed Capital

## Investors

- Grand Yangtze Capital (https://capitalatlas.ai/funds/grand-yangtze-capital) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series A
- InnoMed Capital (https://capitalatlas.ai/funds/innomed-capital) — Series A